Literature DB >> 27694053

Selective anticancer activity of hydroxyapatite/chitosan-poly(d,l)-lactide-co-glycolide particles loaded with an androstane-based cancer inhibitor.

Nenad L Ignjatović1, Katarina M Penov-Gaši2, Victoria M Wu3, Jovana J Ajduković2, Vesna V Kojić4, Dana Vasiljević-Radović5, Maja Kuzmanović1, Vuk Uskoković6, Dragan P Uskoković7.   

Abstract

In an earlier study we demonstrated that hydroxyapatite nanoparticles n class="Chemical">coated with chitosan-poly(d,l)-lactide-co-glycolide (HAp/Ch-PLGA) target lungs following their intravenous injection into mice. In this study we utilize an emulsification process and freeze drying to load the composite HAp/Ch-PLGA particles with 17β-hydroxy-17α-picolyl-androst-5-en-3β-yl-acetate (A), a chemotherapeutic derivative of androstane and a novel compound with a selective anticancer activity against lung cancer cells. 1H NMR and 13C NMR techniques confirmed the intact structure of the derivative A following its entrapment within HAp/Ch-PLGA particles. The thermogravimetric and differential thermal analyses coupled with mass spectrometry were used to assess the thermal degradation products and properties of A-loaded HAp/Ch-PLGA. The loading efficiency, as indicated by the comparison of enthalpies of phase transitions in pure A and A-loaded HAp/Ch-PLGA, equaled 7.47wt.%. The release of A from HAp/Ch-PLGA was sustained, neither exhibiting a burst release nor plateauing after three weeks. Atomic force microscopy and particle size distribution analyses were used to confirm that the particles were spherical with a uniform size distribution of d50=168nm. In vitro cytotoxicity testing of A-loaded HAp/Ch-PLGA using MTT and trypan blue dye exclusion assays demonstrated that the particles were cytotoxic to the A549 human lung carcinoma cell line (46±2%), while simultaneously preserving high viability (83±3%) of regular MRC5 human lung fibroblasts and causing no harm to primary mouse lung fibroblasts. In conclusion, composite A-loaded HAp/Ch-PLGA particles could be seen as promising drug delivery platforms for selective cancer therapies, targeting malignant cells for destruction, while having a significantly lesser cytotoxic effect on the healthy cells.
Copyright © 2016 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Androstane; Chitosan; Hydroxyapatite; Lung cancer; Nanoparticle; PLGA

Mesh:

Substances:

Year:  2016        PMID: 27694053      PMCID: PMC5096963          DOI: 10.1016/j.colsurfb.2016.09.041

Source DB:  PubMed          Journal:  Colloids Surf B Biointerfaces        ISSN: 0927-7765            Impact factor:   5.268


  48 in total

Review 1.  Engineering the nanoparticle-protein interface for cancer therapeutics.

Authors:  Amir Ata Saie; Moumita Ray; Morteza Mahmoudi; Vincent M Rotello
Journal:  Cancer Treat Res       Date:  2015

Review 2.  Multifunctional nanoparticles: cost versus benefit of adding targeting and imaging capabilities.

Authors:  Zhiliang Cheng; Ajlan Al Zaki; James Z Hui; Vladimir R Muzykantov; Andrew Tsourkas
Journal:  Science       Date:  2012-11-16       Impact factor: 47.728

Review 3.  No king without a crown--impact of the nanomaterial-protein corona on nanobiomedicine.

Authors:  Dominic Docter; Sebastian Strieth; Dana Westmeier; Oliver Hayden; Mingyuan Gao; Shirley K Knauer; Roland H Stauber
Journal:  Nanomedicine (Lond)       Date:  2015-02       Impact factor: 5.307

4.  Some studies of crosslinking chitosan-glutaraldehyde interaction in a homogeneous system.

Authors:  O A Monteiro; C Airoldi
Journal:  Int J Biol Macromol       Date:  1999-11       Impact factor: 6.953

5.  Development of drug loaded nanoparticles for tumor targeting. Part 1: Synthesis, characterization, and biological evaluation in 2D cell cultures.

Authors:  Mohammad H El-Dakdouki; Ellen Puré; Xuefei Huang
Journal:  Nanoscale       Date:  2013-03-26       Impact factor: 7.790

6.  Disposition of positively charged Bowman-Birk protease inhibitor conjugates in mice: influence of protein conjugate charge density and size on lung targeting.

Authors:  H Ekrami; A R Kennedy; W C Shen
Journal:  J Pharm Sci       Date:  1995-04       Impact factor: 3.534

7.  A molecular receptor targeted, hydroxyapatite nanocrystal based multi-modal contrast agent.

Authors:  Anusha Ashokan; Deepthy Menon; Shantikumar Nair; Manzoor Koyakutty
Journal:  Biomaterials       Date:  2009-12-24       Impact factor: 12.479

Review 8.  Toward a universal treatment for cancer: cell inflation assisted chemotherapy.

Authors:  Daniel Corcos
Journal:  Cancer Med       Date:  2013-05-28       Impact factor: 4.452

Review 9.  Cancer nanomedicine: from targeted delivery to combination therapy.

Authors:  Xiaoyang Xu; William Ho; Xueqing Zhang; Nicolas Bertrand; Omid Farokhzad
Journal:  Trends Mol Med       Date:  2015-02-02       Impact factor: 11.951

Review 10.  Anticancer and anti-inflammatory properties of chitin and chitosan oligosaccharides.

Authors:  Kazuo Azuma; Tomohiro Osaki; Saburo Minami; Yoshiharu Okamoto
Journal:  J Funct Biomater       Date:  2015-01-14
View more
  4 in total

1.  A Novel Method to Improve the Anticancer Activity of Natural-Based Hydroxyapatite against the Liver Cancer Cell Line HepG2 Using Mesoporous Magnesia as a Micro-Carrier.

Authors: 
Journal:  Molecules       Date:  2017-11-24       Impact factor: 4.411

2.  Chitosan nanobeads loaded with Biginelli hybrids as cell-selective toxicity systems with a homogeneous distribution of the cell cycle in cancer treatment.

Authors:  Jovana Ristovski Trifunović; Željko Žižak; Smilja Marković; Nenad Janković; Nenad Ignjatović
Journal:  RSC Adv       Date:  2020-11-13       Impact factor: 4.036

3.  When Nothing Turns Itself Inside out and Becomes Something: Coating Poly(Lactic-Co-Glycolic Acid) Spheres with Hydroxyapatite Nanoparticles vs. the Other Way Around.

Authors:  Vuk Uskoković; Victoria M Wu
Journal:  J Funct Biomater       Date:  2022-07-23

4.  Effective Targeting of Colon Cancer Cells with Piperine Natural Anticancer Prodrug Using Functionalized Clusters of Hydroxyapatite Nanoparticles.

Authors:  Khaled AbouAitah; Agata Stefanek; Iman M Higazy; Magdalena Janczewska; Anna Swiderska-Sroda; Agnieszka Chodara; Jacek Wojnarowicz; Urszula Szałaj; Samar A Shahein; Ahmed M Aboul-Enein; Faten Abou-Elella; Stanislaw Gierlotka; Tomasz Ciach; Witold Lojkowski
Journal:  Pharmaceutics       Date:  2020-01-16       Impact factor: 6.321

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.